Obesity and weight management

Key obesity facts:
  • Obesity has been recognised as a chronic disease by a number of leading health organisations, including the World Health Organization (WHO) and the American Medical Association.1,2
  • In 2014, more than 1.9 billion adults were overweight. Of these, over 600 million were living with obesity.1
  • Rates of obesity have nearly doubled since 1980.1

Obesity has been recognised by health organisations including the WHO as a chronic disease that requires long-term management.1,2 Obesity has been identified as a health concern primarily due to its associated comorbidities and impact on quality of life. The risk of morbidity and mortality increases with the severity of obesity.15

Research has shown a weight loss of 5-10% in people with obesity can lead to significant health benefits.10,11

Due to the complex nature of obesity there is a need for multiple treatment options that can help people with obesity to lose weight, keep it off, and thereby improve their health.16

Building on our heritage as a world leader in diabetes care and other chronic diseases, Novo Nordisk are committed, long-term, to use our expertise to help people with obesity. For more information and resources about obesity and weight management, please visit our dedicated healthcare professional support website Rethink Obesity®.

Obesity treatments
Saxenda® liraglutide 3 mg  Summary (SmPC)  

 

For more information about ongoing obesity research at Novo Nordisk please click here.

Saxenda®
Saxenda®

At Novo Nordisk, we are committed to improving the understanding and management of obesity. Find out more about the science behind obesity and get resources to help with obesity and weight management at our healthcare professional support website Rethink Obesity®.